Briefings

What is changing in the rules, what it means for your product, your municipality or your project, and who here handles it. In English and Portuguese.

Monitoring reports, cosmetic products

Our monitoring reports record the changes to cosmetics rules in a given period, and we publish one each month. Each one is a dated publication: it reflects the rules on the date it was published and is not updated afterwards. For what applies today, read the latest briefings or ask us.

210 items

Results

Monitoring report

European Union notifies WTO of the draft 19th ATP to CLP Regulation

Ingredients: DIMETHYLTOLYLAMINE, TRIMETHYLBENZOYL DIPHENYLPHOSPHINE OXIDE

Date of draft publication: 02/03/2023

On 2 March 2023, the EU notified the WTO of the 19th ATP to CLP Regulation, potentially impacting a total of 16 substances that can be used in cosmetics, including 2 with new CMR classifications, which ultimately threatens their use in cosmetic products.

Monitoring report

European Commission proposes new Green Claims Directive

Proposal of new EU Green Claims Directive

Date of publication: 22/03/2023

On 22 March 2023, the European Commission proposed a new Green Claims Directive to tackle the growing issue of greenwashing. These new requirements will add to the already implemented Regulation (EU) No. 655/2013 laying down common criteria for the justification of claims used in relation to cosmetic products.

Monitoring report

Preliminary SCCS opinion on Hydroxyapatite (nano)

Ingredients: HYDROXYAPATITE (NANO)

Date of publication: 31/03/2022

On 11 January 2023, the SCCS published the preliminary opinion on Hydroxyapatite (nano). The deadline for comments was set for 1 March 2023.

Monitoring report

France Appeals European General Court Decision Annulling the Harmonized Classification and Labeling of Titanium Dioxide as Carcinogenic

Ingredients: TITANIUM DIOXIDE

Date of publication: 13/02/2023

France has appealed the EU General Court’s decision to annul the classification of titanium dioxide (TiO2) in certain powder forms as carcinogenic. The harmonized classification and labelling of Titanium Dioxide will continue to apply until the appeal has been decided.

Monitoring report

ECHA publishes PFAS restriction proposal

Ingredients: PER- and POLYFLUOROALKYL substances (PFAS)

Date of publication: 07/02/2023

On February 7, 2023, the European Chemicals Agency (ECHA) announced its proposed restrictions on per- and polyfluoroalkyl substances (PFASs).

Monitoring report

Request for SCCS scientific opinion on Hexyl Salicylate

Ingredients: HEXYL SALICYLATE

The European Commission has requested the Scientific Committee on Consumer Safety (SCCS) to assess the safety of Hexyl Salicylate as used in cosmetic products.

Cosmetic Products

Monitoring report

European Commission requests SCCS Opinion on the safety of Cyclamen Aldehyde

Ingredient: CYCLAMEN ALDEHYDE

Date of publication: 8 June 2026

The Scientific Committee on Consumer Safety (SCCS) has accepted a mandate to assess the safety of Cyclamen Aldehyde, following potential classification as a reproductive toxicant under the CLP Regulation.

Monitoring report

European Cosmetics Regulation – Updates on Cosmetic Ingredients  

Topic: NEW RESTRICTIONS ON COSMETIC INGREDIENTS

Date of publication: 13 January 2026

The European Commission published Commission Regulation (EU) 2026/78, which brings new restrictions on several cosmetic ingredients that were classified as Carcinogenic, Mutagenic or Toxic for Reproduction (CMR).

Monitoring report

United Kingdom publishes Technical Report on the Classification and Labelling of Talc 

Ingredient: TALC

Date of publication: January 2026

The United Kingdom (UK) Health and Safety Executive (HSE) has published a technical report concluding that Talc does not warrant carcinogenicity classification, diverging from ECHA's Risk Assessment Committee (RAC) opinion supporting Category 1B classification.

Medical Devices

EU

How to demonstrate equivalence under the MDR

Clinical data from an equivalent device can support your clinical evaluation, but the MDR sets a higher bar than the Directives did. The three characteristics, data access, and documentation.

Follow an area

One email when an area publishes, in the language you choose. Nothing else.